Abstract:ID 98732 Poster Board 486 Addiction to tobacco and nicotine products remains a leading cause of disease and death worldwide, and an increasing number of never-smokers are being exposed to nicotine via e-cigarettes. With only a few moderately efficacious smoking-cessation therapeutics available, achieving long-term abstinence from nicotine addiction is an unattainable goal for millions. The role of brain nicotinic acetylcholine receptors (nAChRs) in nicotine's behavioral effects leading to tobacco addiction is well recognized. However, the neurobiological basis underlying the role of specific nAChRs in nicotine's behavioral effects remains poorly understood. Our recently published findings have emphasized the role of the high-sensitivity isoform of the α4β2 nAChRs (the HS (α4)2(β2)3 nAChR) in nicotine-associated behavior. Therefore, our current efforts are focused on the development of novel positive allosteric modulators (PAMs) that selectively target the HS (α4)2(β2)3 nAChR for in vivo applications to probe the function of this major nAChR subtype as well as for potential therapeutic applications as smoke-cessation aid. Unlike classical nAChR agonists, which bind at the evolutionary conserved ACh binding site, PAMs bind to sites that are less conserved and potentially unique to the HS (α4)2(β2)3 nAChR making the subtype selectively more attenable. In addition, PAMs act only in the presence of the endogenous neurotransmitter, minimizing tonic activation, desensitization, receptor upregulation, and alteration in the pattern of cholinergic synaptic transmission seen with nAChR agonists. Using three nAChR PAM pharmacophores and computational ligand docking predictions, we synthesized a series of derivatives and examined their nAChR PAM activities (ability to enhance ACh-induced current responses) in vitro . Candidates with potent and efficacious in vitro HS (α4)2(β2)3 nAChR PAM activities are currently being evaluated for their ability to reduce nicotine self-intake and withdrawal symptoms in mice.

The Subtype-Selective Nicotinic Acetylcholine Receptor Positive Allosteric Potentiator 2087101 Differentially Facilitates Neurotransmission in the Brain.

Novel Positive Allosteric Modulators of the Human Α7 Nicotinic Acetylcholine Receptor

Chemical Conversion of Nicotinamide into Type I Positive Allosteric Modulator of Α7 Nachrs.

Synthesis and Biological Evaluation of Novel Triazine Derivatives as Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors

An Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor Possessing Cognition-Enhancing Properties in Vivo

Optimizing positive allosteric modulators to selectively target the high sensitivity 23 nicotinic acetylcholine receptor

Pharmacological Properties and Evaluations of a Novel Positive Allosteric Modulator of Α7 Nachr for Attenuation of Schizophrenia-Like Behavior in Mice

Allosteric Activation of α7 Nicotinic Acetylcholine Receptors by Novel 2-Arylamino-thiazole-5-carboxylic Acid Amide Derivatives for the Improvement of Cognitive Deficits in Mice

Preclinical Characterization Of A-582941: A Novel Alpha 7 Neuronal Nicotinic Receptor Agonist With Broad Spectrum Cognition-Enhancing Properties

Design and Synthesis of Novel Positive Allosteric Modulators of Α7 Nicotinic Acetylcholine Receptors with the Ability to Rescue Auditory Gating Deficit in Mice.

Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor

Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders

Partial Agonists for Α4β2 Nicotinic Receptors Stimulate Dopaminergic Neuron Firing with Relatively Enhanced Maximal Effects

α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

Preclinical Characterization of A-582941: A Novel Α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties

The nicotinic α4β2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices

SR9883 is a novel small-molecule enhancer of α4β2* nicotinic acetylcholine receptor signaling that decreases intravenous nicotine self-administration in rats

The Current Agonists and Positive Allosteric Modulators of Α7 Nachr for CNS Indications in Clinical Trials

Synthesis and Biological Evaluation of Novel Hybrids of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists.

The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.

Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation